Financial comparisons Arrowhead Pharmaceuticals, Inc.
Equities
ARWR
US04280A1007
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 61.44 USD | -4.98% |
|
+16.58% | +226.81% |
| 12-02 | Arrowhead Pharmaceuticals Gets FDA Breakthrough Tag for Triglyceride Drug | MT |
| 12-02 | Arrowhead Pharmaceuticals receives FDA breakthrough therapy designation for plozasiran | RE |
Main competitors
| Revenues (N-1) | Net Margin (N-1) | EBIT Margin (N-1) | ROE (N-1) | ROA (N-1) | Leverage (N-1) | ||
|---|---|---|---|---|---|---|---|
 | 829M | -0.2% | 11.86% | 22.1% | - | -7.39x | |
| 2.22B | 36.99% | -0.96% | 2.26% | 2.02% | 818.71x | |
| 364M | -251.24% | -241.47% | -1,601.19% | -54.47% | 0.16x | |
| 5.38B | 24.08% | 29.51% | 16.78% | 12.27% | -0.97x | |
| 2.85B | -24.18% | -47.77% | -3.3% | -2.88% | 9.36x | |
| 2.99B | 36.44% | 32.53% | 22.97% | 19.34% | -2.97x | |
| 2.56B | 17.97% | 25.37% | 11.65% | 8.43% | -0.66x | |
| 291M | -24.22% | -26.28% | -8.94% | -4.69% | -2.82x | |
| 265M | -13.8% | -7.18% | -9.46% | -9.11% | 18.95x | |
| 180M | -258.64% | -276.39% | -80.35% | - | 1.63x | |
| 2.17B | 24.04% | 27.88% | 23.13% | 17.7% | -1.75x | |
| 18.47M | -3,191.11% | -2,902.72% | - | -52.97% | 0.77x | |
| 22.61M | -165.69% | -177.21% | -45.83% | -28.23% | 1.93x | |
| 36.13M | -595.93% | -752.96% | -42.88% | - | 1.96x | |
| Average | 1.44B | -313.25% | -307.56% | -130.24% | -8.42% | 59.78x | |
| Weighted average by Cap. | 1.98B | -150.76% | -153.9% | -256.04% | -7.72% | 161.19x |
- Stock Market
- Equities
- ARWR Stock
- Sector Arrowhead Pharmaceuticals, Inc.
- Financial comparisons
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition